Related Experiment Video
Updated: Dec 25, 2025
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.7K
Abstract:
Chlorotoxin, a small peptide component of scorpion venom, may help pinpoint glioblastoma cells for destruction when engineered into a chimeric antigen receptor T-cell therapy. The concept has shown efficacy in mice, without off-target toxicity, and will soon be assessed in patients.
Insights
Chimeric antigen receptor T-cell therapy using chlorotoxin may precisely target glioblastoma cells. This innovative approach demonstrated efficacy and safety in mice, with human trials forthcoming.
Area of Science:
- Oncology
- Immunotherapy
- Neuroscience
Background:
- Glioblastoma is an aggressive brain tumor with limited treatment options.
- Current therapies often cause significant side effects.
- Targeting glioblastoma specifically is a major challenge in neuro-oncology.
Discussion:
- Chlorotoxin, a peptide from scorpion venom, can be engineered into chimeric antigen receptor (CAR) T-cells.
- This engineered CAR T-cell therapy aims to specifically identify and destroy glioblastoma cells.
- The strategy leverages the unique properties of chlorotoxin for targeted cancer cell recognition.
Key Insights:
- Preclinical studies in mice show promising efficacy of chlorotoxin-engineered CAR T-cells against glioblastoma.
- The therapy demonstrated a lack of off-target toxicity in the animal models.
- This suggests a potential for a safer and more effective glioblastoma treatment.
Outlook:
- Human clinical trials are planned to evaluate the safety and efficacy in patients.
- This research could lead to a novel therapeutic strategy for glioblastoma.
- Further development may expand the application of this targeted immunotherapy approach.
